|
A.A. Rumyantsev
Current aspects of the treatment of brca-associated ovarian cancer
|
7-13 |
|
Yu.N. Zubkova, I.A. Kurmukov, O.A. Obukhova, Sh.R. Kashia
The relevance of the use of psychotropic drugs in clinical oncology
|
14-20 |
|
I.V. Samoylenko, Ya.I. Zhulikov, L.V. Demidov
Tumors hyperprogression phenomenon against the background of the use of PD1 blocators: myths or reality?
|
22-28 |
|
E.A. Ulrikh (1, 2), T.Yu. Semiglazova (1), D.I. Khalimbekova (1), O.A. Smirnova (1), D.G. Ulrikh (2), A.F. Urmancheeva (1)
Potentials of drug therapy for metastatic/recurrent cervical cancer
|
29-32 |
|
M.Yu. Kichigina (1), E.A. Demina (2), G.S. Tumyan (1), E.A. Osmanov (3), P.A. Zeynalova (1)
Potentials of nivolumab in the treatment of refractory Hodgkin’s lymphoma: literature review and authors’ own observation
|
33-38 |
|
V.F. Semiglazov (1), V.V. Semiglazov (2), K.S. Nikolaev (1), G.A. Dashyan (1), A.V. Komyakhov (1), R.M. Paltuev (1), V.S. Appolonova (1), R.V. Donskikh (1), A.I. Tseluyko (1), T.Yu. Semiglazova (1), E.K. Zhiltsova (1), P.V. Krivorotko (1)
Ways to improve efficiency of endocrinotherapy of breast cancer: new targeted cells, new therapeutic opportunities
|
39-48 |
ORIGINAL ARTICLES |
|
G.R. Abuzarova (1), G.S. Alekseeva (2), R.R. Sarmanayeva (1), S.E. Lapina (1)
Sehydrin as a drug of accompanying therapy to improve the quality of life and reduce chronic pain in cancer patients of palliative profile
|
49-54 |
|
M.Yu. Fedyanin, Kh.Kh.-M. Elsnukaeva, I.A. Pokataev, O.V. Sekhina, D.A. Chekini, A.A. Bulanov, A.A. Tryakin, S.A. Tyulyandin
Efficacy and safety of therapy with biosimilar bevacizumab in the treatment of patients with metastatic colon cancer – a series of clinical observations
|
55-59 |
|
N.D. Faseeva, S.A. Kuleva
Germ cell tumors in children: 20-year experience of treatment in the N.N. Petrov National Medical Research Center of Oncology
|
60-65 |
|
|
A.E. Kuzminov, V.A. Gorbunova
Neuroendocrine tumors: general characteristics and features of management tactics
|
66-71 |
|
A.A. Markovich
Features of the clinical manifestations of nets. Carcinoid syndrome
|
72-75 |
|
G.S. Еmelyanova (1), N.F. Orel (2), A.S. Odintsova (1), V.A.Gorbunova (1)
Pharmacotherapy of neuroendocrine tumors
|
76-80 |
|
T.E. Byalik
Venetoclax in clinical studies
|
81-84 |
|
I.A. Antyukhova, B.M. Medvedeva, A.B. Lukyanchenko
Difficulties of X-ray diagnostics of ectopic splenic tissue
|
85-89 |
|
M.D. Budurova (1), M.R. Kanzapetov (1), M.M. Davydov (1), S.S. Gerasimov (1), V.A. Khaylenko (2)
Non-small cell lung cancer complicated by bleeding: a clinical case
|
90-96 |
|
I.G. Bakulin, I.A. Oganezova, O.I. Medvedeva, V.V. Petrenko, Yu.V. Medvedev
Multiple myeloma, secondary liver amiloidosis. Description of the clinical case
|
98-104 |
|
S.K. Zyryanov (1), M.Yu. Frolov (2, 3), M.V. Zhuravleva (4), V.A. Rogov (2), D.D. Sakaeva (5)
Pharmacoeconomic analysis of pembrolizumab in combination with chemotherapy as the first line of advances non-squamous non-small cell lung cancer treatment
|
105-114 |
Русский
